Sponsor

Yuhan Corporation

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Yuhan Corporation appears in 48 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials48
Recruiting shown5
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

48 shown
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid TumorsNCT06975410 · lead sponsor · 2025-06-12
RECRUITING
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946NCT06616766 · lead sponsor · 2024-10-02
RECRUITING
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid TumorNCT05523947 · lead sponsor · 2022-08-26
RECRUITING
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential HypertensionNCT06041529 · lead sponsor · 2023-10-18
ACTIVE_NOT_RECRUITING
An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and ASNCT05835518 · lead sponsor · 2023-01-26
UNKNOWN
Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR MutationNCT06247280 · lead sponsor · 2022-06-24
ACTIVE_NOT_RECRUITING
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential HypertensionNCT06282549 · lead sponsor · 2022-06-08
ACTIVE_NOT_RECRUITING
Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.NCT05162274 · lead sponsor · 2021-11-30
COMPLETED
Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and HypercholesterolemiaNCT06293261 · lead sponsor · 2020-06-27
COMPLETED
A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic PainNCT05624853 · lead sponsor · 2020-05-12
COMPLETED
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)NCT04248829 · lead sponsor · 2020-02-13
COMPLETED
Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With DyslipidemiaNCT03951207 · lead sponsor · 2019-05-30
COMPLETED
Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DMNCT03597412 · lead sponsor · 2018-10-17
COMPLETED
Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy VolunteersNCT03662620 · lead sponsor · 2018-10-05
COMPLETED
Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448NCT03556436 · lead sponsor · 2018-07-03
COMPLETED
Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's DementiaNCT03441516 · lead sponsor · 2018-04-19
UNKNOWN
High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and HypertensionNCT03474562 · lead sponsor · 2018-04-03
COMPLETED
High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 DiabetesNCT03403556 · lead sponsor · 2018-03-27
UNKNOWN
Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and HypercholesterolemiaNCT03446261 · lead sponsor · 2018-02-23
COMPLETED
Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With HypertensionNCT03267329 · lead sponsor · 2017-09-11
COMPLETED
A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and HypercholesterolemiaNCT03217409 · lead sponsor · 2017-08-10
COMPLETED
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706NCT03235362 · lead sponsor · 2017-08-07
COMPLETED
Clinical Trial to Evaluate the Efficacy and Safety of YHP1701NCT03103256 · lead sponsor · 2017-05-17
COMPLETED
Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and RosuvastatinNCT03116516 · lead sponsor · 2017-04-21
COMPLETED
Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and HyperlipidemiaNCT03067688 · lead sponsor · 2017-04-11
COMPLETED
Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLCNCT03046992 · lead sponsor · 2017-02-15
COMPLETED
A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and RosuvastatinNCT02951962 · lead sponsor · 2016-08-01
COMPLETED
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine TreatmentNCT02620163 · lead sponsor · 2015-12-01
COMPLETED
Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II DiabetesNCT02586129 · lead sponsor · 2015-11-04
COMPLETED
PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and RosuvastatinNCT02608242 · lead sponsor · 2015-11-01
TERMINATED
PK Study of YH22162 FDC Compared to Combination of Twynsta and HygrotonNCT02496910 · lead sponsor · 2015-06-01
COMPLETED
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLCNCT05862194 · lead sponsor · 2015-06-01
COMPLETED
Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)NCT02152969 · lead sponsor · 2014-05-01
COMPLETED
Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and HyperlipidemiaNCT01914432 · lead sponsor · 2013-11-01
COMPLETED
PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and RosuvastatinNCT01975961 · lead sponsor · 2013-07-01
COMPLETED
Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)NCT01869881 · lead sponsor · 2013-02-01
COMPLETED
Safety and Efficacy of YH14617 in Diabetes MellitusNCT01507038 · lead sponsor · 2011-12-01
COMPLETED
Pharmacokinetic Drug Interaction Between Rosuvastatin and ValsartanNCT01609907 · lead sponsor · 2011-11-01
COMPLETED
Safety and Efficacy of YHD001 in AsthmaNCT01424124 · lead sponsor · 2011-11-01
COMPLETED
Early Access Program of Lazertinib in Republic of KoreaNCT04829422 · lead sponsor
APPROVED_FOR_MARKETING
Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)NCT07359105 · collaborator · 2026-03-09
RECRUITING
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid BiopsyNCT05469022 · collaborator · 2022-05-19
RECRUITING
Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)NCT05579626 · collaborator · 2023-03-14
ENROLLING_BY_INVITATION
Impact of Lazertinib Dose Modification on Effectiveness and SafetyNCT05716672 · collaborator · 2023-02-01
UNKNOWN
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation TherapyNCT05338619 · collaborator · 2022-06-30
UNKNOWN
A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)NCT04075396 · collaborator · 2019-10-16
COMPLETED
Amlodipine Versus Valsartan for Improvement of Diastolic Dysfunction Associated With HypertensionNCT02973035 · collaborator · 2016-12-01
COMPLETED
Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' StudyNCT02294643 · collaborator · 2009-04-01
COMPLETED

Drugs studied in this sponsor's trials

12 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Yuhan Corporation as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
lazertinib4
rosuvastatin3
telmisartan3
amlodipine2
aspirin1
chlorthalidone1
clopidogrel1
gefitinib 250 MG1
lazertinib RxCUI 2691150 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 4 trials rosuvastatin RxCUI 301542 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials telmisartan RxCUI 73494 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials amlodipine RxCUI 17767 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials aspirin RxCUI 1191 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial chlorthalidone RxCUI 2409 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial clopidogrel RxCUI 32968 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial gefitinib 250 MG RxCUI 358777 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial lazertinib 240 MG RxCUI 2691163 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial metformin RxCUI 6809 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial Singulair RxCUI 153889 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial valsartan RxCUI 69749 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor40
collaborator8
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.